Are we ready to endorse new multiple cancer early-detection tests?
1 Women and Babies Clinic, Central Building, Hong Kong, SAR, China.
2 Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, SAR, China.
Short Communication
World Journal of Advanced Research and Reviews, 2023, 17(02), 800–802
Article DOI: 10.30574/wjarr.2023.17.2.0325
Publication history:
Received on 13 January 2023; revised on 16 February 2023; accepted on 24 February 2023
Abstract:
Cancer detection tests open a new era of developing cancer markers, allowing early detection and improving cancer treatments. Existing cancer detection technologies, for example, CA125, CA 19.9, CT, MRI, and others, are either not highly sensitive or specific enough for early detection. Recent technological development of “liquid biopsy” research led to more sensitive biomarkers. Newly developed multiple-cancer early-detection tests can screen up to multiple cancers in asymptomatic individuals with one blood draw. These tests, however, might pose significant challenges in our clinical practice. This paper highlights the issues we face and how to solve their problems.
Keywords:
Cancer detection test; Biomarkers; MCED tests; NHS-Galleri trial
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0